Fig. 1From: The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week studyStudy design. BLISS, Study of Belimumab in Subjects with SLE; LTD, long-term discontinuation; OLE, open-label extension; TC, treatment continuation; TH, treatment holidayBack to article page